Showing 64,121 - 64,140 results of 124,369 for search '(( 2 d decrease ) OR ( 5 ((we decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 2.52s Refine Results
  1. 64121
  2. 64122
  3. 64123

    Temporal trends in adolescents’ self-reported psychosomatic health complaints from 1980-2016: A systematic review and meta-analysis by Thomas Potrebny (4624135)

    Published 2017
    “…In the descriptive analysis, 10 studies indicated a trend of increasing PSHC, eight showed a stable trend and three showed a decreasing trend at certain points in time. …”
  4. 64124

    Table_1_FXS-Like Phenotype in Two Unrelated Patients Carrying a Methylated Premutation of the FMR1 Gene.docx by Esperanza Fernández (5922350)

    Published 2018
    “…<p>Fragile X syndrome (FXS) is mostly caused by two distinct events that occur in the FMR1 gene (Xq27.3): an expansion above 200 repeats of a CGG triplet located in the 5′UTR of the gene, and methylation of the cytosines located in the CpG islands upstream of the CGG repeats. …”
  5. 64125

    DataSheet_1_A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.xls by Mingyi Yang (11894078)

    Published 2022
    “…Objective<p>Osteosarcoma (OS) is a common bone malignancy with poor prognosis. We aimed to investigate the relationship between cuproptosis-related lncRNAs (CRLncs) and the survival outcomes of patients with OS.…”
  6. 64126

    DataSheet_3_A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.xls by Mingyi Yang (11894078)

    Published 2022
    “…Objective<p>Osteosarcoma (OS) is a common bone malignancy with poor prognosis. We aimed to investigate the relationship between cuproptosis-related lncRNAs (CRLncs) and the survival outcomes of patients with OS.…”
  7. 64127

    DataSheet_2_A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.xls by Mingyi Yang (11894078)

    Published 2022
    “…Objective<p>Osteosarcoma (OS) is a common bone malignancy with poor prognosis. We aimed to investigate the relationship between cuproptosis-related lncRNAs (CRLncs) and the survival outcomes of patients with OS.…”
  8. 64128
  9. 64129

    The Malnutrition-Related Increase in Early Visceralization of <i>Leishmania donovani</i> Is Associated with a Reduced Number of Lymph Node Phagocytes and Altered Conduit System Flo... by Marwa K. Ibrahim (446138)

    Published 2013
    “…<div><p>In a murine model of moderate childhood malnutrition we found that polynutrient deficiency led to a 4–5-fold increase in early visceralization of <i>L. donovani</i> (3 days post-infection) following cutaneous infection and a 16-fold decrease in lymph node barrier function (p<0.04 for all). …”
  10. 64130

    Image_1_A Fenton-like cation can improve arsenic trioxide treatment of sclerodermatous chronic Graft-versus-Host Disease in mice.tif by Charlotte Chêne (11221620)

    Published 2022
    “…In vivo, in a cGvHD mouse model, daily injections of ATO 2.5 µg/g + CuCl<sub>2</sub> 0.5 µg/g induce a decrease in lymphocyte activation and fibrosis that was equivalent to that induced by ATO 5 µg/g. …”
  11. 64131

    Image_4_A Fenton-like cation can improve arsenic trioxide treatment of sclerodermatous chronic Graft-versus-Host Disease in mice.tif by Charlotte Chêne (11221620)

    Published 2022
    “…In vivo, in a cGvHD mouse model, daily injections of ATO 2.5 µg/g + CuCl<sub>2</sub> 0.5 µg/g induce a decrease in lymphocyte activation and fibrosis that was equivalent to that induced by ATO 5 µg/g. …”
  12. 64132

    Image_6_A Fenton-like cation can improve arsenic trioxide treatment of sclerodermatous chronic Graft-versus-Host Disease in mice.tif by Charlotte Chêne (11221620)

    Published 2022
    “…In vivo, in a cGvHD mouse model, daily injections of ATO 2.5 µg/g + CuCl<sub>2</sub> 0.5 µg/g induce a decrease in lymphocyte activation and fibrosis that was equivalent to that induced by ATO 5 µg/g. …”
  13. 64133

    Table_1_A Fenton-like cation can improve arsenic trioxide treatment of sclerodermatous chronic Graft-versus-Host Disease in mice.pdf by Charlotte Chêne (11221620)

    Published 2022
    “…In vivo, in a cGvHD mouse model, daily injections of ATO 2.5 µg/g + CuCl<sub>2</sub> 0.5 µg/g induce a decrease in lymphocyte activation and fibrosis that was equivalent to that induced by ATO 5 µg/g. …”
  14. 64134

    Image_2_A Fenton-like cation can improve arsenic trioxide treatment of sclerodermatous chronic Graft-versus-Host Disease in mice.tif by Charlotte Chêne (11221620)

    Published 2022
    “…In vivo, in a cGvHD mouse model, daily injections of ATO 2.5 µg/g + CuCl<sub>2</sub> 0.5 µg/g induce a decrease in lymphocyte activation and fibrosis that was equivalent to that induced by ATO 5 µg/g. …”
  15. 64135

    Image_3_A Fenton-like cation can improve arsenic trioxide treatment of sclerodermatous chronic Graft-versus-Host Disease in mice.tif by Charlotte Chêne (11221620)

    Published 2022
    “…In vivo, in a cGvHD mouse model, daily injections of ATO 2.5 µg/g + CuCl<sub>2</sub> 0.5 µg/g induce a decrease in lymphocyte activation and fibrosis that was equivalent to that induced by ATO 5 µg/g. …”
  16. 64136

    GdA’s effect on morphological variation differs in yeast strains possessing spontaneous mutations or recombinations, as compared to natural yeast isolates. by Kerry A. Geiler-Samerotte (462866)

    Published 2016
    “…(D) For the PC indicated by grey arrows in panels A–C, these plots display the average morphologies for each strain in GdA+ and GdA− conditions as well as the between-strain variation (blue and red bars), which decreases in GdA+ for MA and Rec lines but increases in other strain collections. …”
  17. 64137

    Fetal Movement Counting Improved Identification of Fetal Growth Restriction and Perinatal Outcomes – a Multi-Centre, Randomized, Controlled Trial by Eli Saastad (190836)

    Published 2011
    “…<div><h3>Background</h3><p>Fetal movement counting is a method used by the mother to quantify her baby's movements, and may prevent adverse pregnancy outcome by a timely evaluation of fetal health when the woman reports decreased fetal movements. …”
  18. 64138
  19. 64139
  20. 64140